

Oliver SchÄffski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12059365/publications.pdf>

Version: 2024-02-01

17
papers

1,006
citations

759233

12
h-index

888059

17
g-index

17
all docs

17
docs citations

17
times ranked

1323
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1116-1119.	1.2	11
2	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. <i>JAMA Dermatology</i> , 2021, 157, 1066.	4.1	24
3	Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 – A ten-year overview. <i>Epilepsy and Behavior</i> , 2018, 83, 28-35.	1.7	57
4	Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. <i>Epilepsy and Behavior</i> , 2016, 64, 75-82.	1.7	26
5	Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) – study protocol for a pragmatic randomized controlled trial. <i>BMC Family Practice</i> , 2016, 17, 49.	2.9	14
6	Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list. <i>BMC Health Services Research</i> , 2016, 16, 109.	2.2	14
7	Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project. <i>Oncology</i> , 2015, 88, 103-121.	1.9	9
8	Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 176-186.	1.9	55
9	Palliative treatment of colorectal cancer in Germany: cost of care and quality of life. <i>European Journal of Health Economics</i> , 2013, 14, 629-638.	2.8	12
10	Effects of pay for performance in health care: A systematic review of systematic reviews. <i>Health Policy</i> , 2013, 110, 115-130.	3.0	405
11	Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany – a nationwide population-based study in children and adults. <i>Journal of Neurology</i> , 2012, 259, 2376-2384.	3.6	116
12	Economic evaluation of pay-for-performance in health care: a systematic review. <i>European Journal of Health Economics</i> , 2012, 13, 755-767.	2.8	82
13	Bewertung der Einsparpotenziale in der Arzneimitteltherapie durch Dosisanpassung an die Polymorphismen im Cytochrom P450. <i>PharmacoEconomics - German Research Articles</i> , 2012, 10, 69-85.	0.1	1
14	Costs of acute stroke care on regular neurological wards: A comparison with stroke unit setting. <i>Health Policy</i> , 2007, 81, 339-349.	3.0	37
15	Resource Utilization and Costs of Stroke Unit Care in Germany. <i>Value in Health</i> , 2004, 7, 144-152.	0.3	67
16	What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. <i>Health Policy</i> , 1998, 44, 253-260.	3.0	40
17	Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany. <i>PharmacoEconomics</i> , 1996, 10, 37-47.	3.3	36